Rigel Pharmaceuticals, Inc. (RIGL) has a consensus analyst rating of Buy, based on 15 analysts covering the stock. Of those, 8 recommend buying, 7 recommend holding, and 0 recommend selling.
The analyst consensus price target for RIGL is $40.00, representing a +27.4% upside from the current price of $31.39. Price targets range from a low of $38.00 to a high of $42.00.
